Activated CD11b+ CD15+ granulocytes increase in the blood of patients with uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 9, 2009, Pages 4295-4303

  McKenna, Kyle C ^a   Beatty, Kelly M ^a   Bilonick, Richard A ^a   Schoenfield, Lynn ^b   Lathrop, Kira L ^a   Singh, Arun D ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD3 ANTIGEN; CD3ZETA ANTIGEN; CD68 ANTIGEN; UNCLASSIFIED DRUG; CD3E PROTEIN, HUMAN; ITGAM PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UVEA MELANOMA; BLOOD; BRACHYTHERAPY; DENSITY GRADIENT CENTRIFUGATION; ENUCLEATION; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; MIDDLE AGED; T LYMPHOCYTE; UVEA TUMOR;

AGED; AGED, 80 AND OVER; ANTIGENS, CD11B; ANTIGENS, CD15; ANTIGENS, CD3; BRACHYTHERAPY; CENTRIFUGATION, DENSITY GRADIENT; EYE ENUCLEATION; FEMALE; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES; UVEAL NEOPLASMS;

EID: 70349247889     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-3012     Document Type: Article

References (39)

1. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-965.
2. van Dinten LC, Pul N, van Nieuwpoort AF, Out CJ, Jager MJ, van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci. 2005;46:24-30.
3. Kan-Mitchell J, Liggett PE, Harel W, et al. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother. 1991;33:333-340.
4. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res. 1998;17:165-173.
5. de Waard-Siebinga I, Hilders CG, Hansen BE, van Delft JL, Jager MJ. HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 1996;234:34-42.
6. Durie FH, Campbell AM, Lee WR, Damato BE. Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci. 1990;31:2106-2110.
7. Meecham WJ, Char DH, Kaleta-Michaels S. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res. 1992; 24:20-26.
8. de la Cruz PO Jr, Specht CS, McLean IW. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990;65:112-115.
9. Ma D, Luyten GP, Luider TM, Niederkorn JY. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995;36:435-441.
10. Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004;45:2056-2064.
11. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68 cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:1414-1421.
12. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49:505-510.
13. McKenna KC, Kapp JA. Accumulation of immunosuppressive CD11b myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J Immunol. 2006;177: 1599-1608.
14. +) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J Immunol. 2001;167:5583-5593.
15. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumorassociated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880-4891.
16. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003;102:2138-2145.
17. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162-179.
18. Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044-3048.
19. Schmielau J, Finn OJ. Activated granulocytes and granulocytederived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61:4756-4760.
20. Zea AH, Rodriguez PC, Culotta KS, et al. L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004;232:21-31.
21. Berman NG, Wong WK, Bhasin S, Ipp E. Applications of segmented regression models for biomedical studies. Am J Physiol. 1996;270:E723-E732.
22. Nicholson JK, Jones BM, Cross GD, McDougal JS. Comparison of T and B cell analyses on fresh and aged blood. J Immunol Methods. 1984;73:29-40.
23. + granulocytes which inhibit T cell function. J Immunol Methods. 2009;341(1-2):68-75.
24. Baniyash M. TCR zeta-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004;4: 675-687.
25. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109: 1568-1573.
26. Shenton D, Smirnova JB, Selley JN, et al. Global translational responses to oxidative stress impact upon multiple levels of protein synthesis. J Biol Chem. 2006;281:29011-29021.
27. Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A. 1996;93:13119-13124.
28. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992;258: 1795-1798.
29. Recktenwald CV, Kellner R, Lichtenfels R, Seliger B. Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. Cancer Res. 2008;68:10086-10093.
30. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res. 2001;61:1100-1106.
31. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem. 1998;273:22635-22639.
32. Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176:6752-6761.
33. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123-1131.
34. Staibano S, Mascolo M, Tranfa F, et al. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int J Immunopathol Pharmacol. 2006;19:171-179.
35. + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res. 2001;7:947S-957S.
36. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloidderived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636-645.
37. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008; 205:2235-2249.
38. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181: 4666-4675.
39. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calciumbinding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37-51.